The Safety and Efficacy of a Two-Dose Daclizumab (Zenapax) Induction Therapy in Liver Transplant Recipients1

Abstract

In the pilot study, induction therapy with daclizumab was safe, facilitated improvement in renal function, and appeared to reduce the incidence of acute rejection. Combination therapy with daclizumab may be an important adjunct in immunosuppressive strategies for liver transplant recipients.

Combination Prophylaxis with Ganciclovir and Cytomegalovirus (CMV) Immune Globulin After Lung Transplantation: Effective CMV Prevention Following Daclizumab Induction

“…Daclizumab has been proven to be efficacious in decreasing acute rejection in kidney, liver, and heart transplantation (11)(12)(13)(14).…”

Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma

“…On the basis of the efficacy in these multicenter trials and the lack of associated increase in toxicity, in 1997 the FDA provided marketing clearance for the use of daclizumab in the prevention of acute kidney transplant rejection. In subsequent studies, in clinical trials involving a large group of recipients, daclizumab provided a reduction in the rejection episodes in patients receiving renal, liver, cardiac and pancreatic islet transplants (Beniaminovitz et al, 2000;Eckhoff et al, 2000;Shapiro et al, 2000).…”

Clinically useful monoclonal antibodies in treatment

“…Daclizumab may also have beneficial effects in cardiac transplantation and liver transplantation, but the drug combinations have yet to be resolved. [51][52][53] Daclizumab and Basiliximab appear to have favourable safety profiles and do not induce cytokine release syndromes. Rates of infection and early malignancy appear to be similar to conventional drug regimens, although careful analysis of concurrent drug use is required.…”